Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis.

Bibiloni R, Fedorak RN, Tannock GW, Madsen KL, Gionchetti P, Campieri M, De Simone C, Sartor RB.

Am J Gastroenterol. 2005 Jul;100(7):1539-46.

PMID:
15984978
2.

Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.

Huynh HQ, deBruyn J, Guan L, Diaz H, Li M, Girgis S, Turner J, Fedorak R, Madsen K.

Inflamm Bowel Dis. 2009 May;15(5):760-8. doi: 10.1002/ibd.20816.

PMID:
19067432
3.

Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis.

Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A.

Am J Gastroenterol. 2009 Feb;104(2):437-43. doi: 10.1038/ajg.2008.118. Epub 2009 Jan 20.

PMID:
19174792
4.

The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis.

Sood A, Midha V, Makharia GK, Ahuja V, Singal D, Goswami P, Tandon RK.

Clin Gastroenterol Hepatol. 2009 Nov;7(11):1202-9, 1209.e1. doi: 10.1016/j.cgh.2009.07.016. Epub 2009 Jul 22.

PMID:
19631292
5.

[Effect of a probiotic preparation (VSL#3) in patients with mild to moderate ulcerative colitis].

Lee JH, Moon G, Kwon HJ, Jung WJ, Seo PJ, Baec TY, Lee JH, Kim HS.

Korean J Gastroenterol. 2012 Aug;60(2):94-101. Korean.

6.

Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.

Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A.

Am J Gastroenterol. 2010 Oct;105(10):2218-27. doi: 10.1038/ajg.2010.218. Epub 2010 Jun 1.

7.

Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.

Kühbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Fölsch UR, Kamm MA, Schreiber S.

Gut. 2006 Jun;55(6):833-41. Epub 2006 Jan 9.

8.

Probiotic mix VSL#3 is effective adjunctive therapy for mild to moderately active ulcerative colitis: a meta-analysis.

Mardini HE, Grigorian AY.

Inflamm Bowel Dis. 2014 Sep;20(9):1562-7. doi: 10.1097/MIB.0000000000000084.

PMID:
24918321
9.

VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases.

Chapman TM, Plosker GL, Figgitt DP.

Drugs. 2006;66(10):1371-87. Review.

PMID:
16903771
10.

Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis.

Ng SC, Plamondon S, Kamm MA, Hart AL, Al-Hassi HO, Guenther T, Stagg AJ, Knight SC.

Inflamm Bowel Dis. 2010 Aug;16(8):1286-98. doi: 10.1002/ibd.21222.

PMID:
20155842
11.

Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy.

Tsuda Y, Yoshimatsu Y, Aoki H, Nakamura K, Irie M, Fukuda K, Hosoe N, Takada N, Shirai K, Suzuki Y.

Scand J Gastroenterol. 2007 Nov;42(11):1306-11.

PMID:
17852859
12.

Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.

Venturi A, Gionchetti P, Rizzello F, Johansson R, Zucconi E, Brigidi P, Matteuzzi D, Campieri M.

Aliment Pharmacol Ther. 1999 Aug;13(8):1103-8.

13.

Probiotics for maintenance of remission in ulcerative colitis.

Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD007443. doi: 10.1002/14651858.CD007443.pub2. Review.

PMID:
22161412
14.

Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.

Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS.

Cochrane Database Syst Rev. 2015 Nov 23;(11):CD001176. doi: 10.1002/14651858.CD001176.pub3. Review.

15.

Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.

Tursi A, Brandimarte G, Giorgetti GM, Forti G, Modeo ME, Gigliobianco A.

Med Sci Monit. 2004 Nov;10(11):PI126-31. Epub 2004 Oct 26.

PMID:
15507864
16.

Spotlight on VSL#3 probiotic mixture in chronic inflammatory bowel diseases.

Chapman TM, Plosker GL, Figgitt DP.

BioDrugs. 2007;21(1):61-3. Review.

PMID:
17263590
17.

Probiotics for maintaining remission of ulcerative colitis in adults.

Do VT, Baird BG, Kockler DR.

Ann Pharmacother. 2010 Mar;44(3):565-71. doi: 10.1345/aph.1M498. Epub 2010 Feb 2. Review.

PMID:
20124461
18.

Probiotics are a good choice in remission of inflammatory bowel diseases: A meta analysis and systematic review.

Ganji-Arjenaki M, Rafieian-Kopaei M.

J Cell Physiol. 2018 Mar;233(3):2091-2103. doi: 10.1002/jcp.25911. Epub 2017 May 3. Review.

PMID:
28294322
19.

Probiotics in the Management of Ulcerative Colitis.

Chibbar R, Dieleman LA.

J Clin Gastroenterol. 2015 Nov-Dec;49 Suppl 1:S50-5. doi: 10.1097/MCG.0000000000000368. Review.

PMID:
26447965
20.

Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

Yoshimatsu Y, Yamada A, Furukawa R, Sono K, Osamura A, Nakamura K, Aoki H, Tsuda Y, Hosoe N, Takada N, Suzuki Y.

World J Gastroenterol. 2015 May 21;21(19):5985-94. doi: 10.3748/wjg.v21.i19.5985.

Supplemental Content

Support Center